Background We conducted a phase 3, randomized, double-blind, placebo-controlled trial of
sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients …

Background Vascular endothelial growth factor (VEGF) inhibition is a valid therapeutic
approach in renal cell carcinoma. Therefore, an investigation of the combination treatment of the …

Background Recombinant human interleukin-2 (aldesleukin) and recombinant human interferon
alfa can induce notable tumor regression in a limited number of patients with metastatic …

Background Patients with renal-cell carcinoma who undergo nephrectomy have no options
for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting …

Background Cytoreductive nephrectomy has been the standard of care in metastatic renal-cell
carcinoma for 20 years, supported by randomized trials and large, retrospective studies. …

… Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Negrier, Christine
Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin …

Background Survival outcomes are poor for patients with metastatic urothelial carcinoma
who receive standard, first-line, platinum-based chemotherapy. We assessed the overall …

Purpose: To identify survival predictors and to design a prognostic score useful for
distinguishing risk groups in immunocompetent patients with primary CNS lymphomas (PCNSL). …

Purpose The objective of this phase II trial was to assess the efficacy and toxicity of weekly
paclitaxel for patients with metastatic or unresectable angiosarcoma. Patients and Methods …

Purpose The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients
with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that a …